NCT06360692

Brief Summary

This will be a multicenter prospective descriptive case series study following a cohort. The micropigmentation/tattoo procedure will be carried out following the protocol established in each center (see annex x). The present investigation only involves measuring the impact that this technique has on the patients by collecting data in digital format before and after the CAP micropigmentation/tattoo that motivated their visit to the clinical service. CAP micropigmentation/tattooing is usually performed between 6 and 12 months after the breast reconstructive surgery has been completed, sufficient time for healing to complete and the breast to stabilize, although it can be performed from 2 months after the intervention. Nurses are responsible for performing micropigmentation/tattooing of the areola and nipple in mastectomized women.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jun 2024

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 8, 2024

Completed
1 month until next milestone

First Posted

Study publicly available on registry

April 11, 2024

Completed
2 months until next milestone

Study Start

First participant enrolled

June 1, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 30, 2024

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

April 11, 2024

Status Verified

April 1, 2024

Enrollment Period

5 months

First QC Date

March 8, 2024

Last Update Submit

April 10, 2024

Conditions

Keywords

breast cancernipple tattoing,micropigmentation

Outcome Measures

Primary Outcomes (1)

  • Body imagen

    Hopwood Body Image Scale (BIS). Validated in Spanish by Gómez-Campelo \& Bragado-Álvarez. This questionnaire presents Cronbach's alpha of 0.84 in the internal consistency analysis for Latina women with breast cancer and 0.93 in the general Spanish population. The questionnaire consists of 10 items that evaluate several dimensions of body image in cancer patients: affective, behavioral and cognitive. Items are scored on a four-point scale (0=not at all, 1=a little, 2=quite a bit, 3=a lot). The total score is the sum of the 10 items and ranges between 0 and 30. Higher scores correspond to a negative body image. The BIS is a brief, easy self-report instrument that is applicable to patients with any type of cancer, stage of disease, or treatment. Its use has increased in recent years, becoming a reference measure in international research.

    base, 3 months, 12 months

Secondary Outcomes (3)

  • Self-esteem

    base, 3 months, 12 months

  • Sexual Function

    base, 3 months, 12 months

  • Intimacy with the partner

    base, 3 months, 12 months

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

women undergoing micropigmentation of the areola-nipple complex in mastectomized patients who have undergone breast reconstruction treated in the following services: Plastic Surgery of the General University Hospital of Valencia (Spain), the Breast Micropigmentation Unit of the Puerta del Hierro Hospital in Madrid (Spain) and the Breast Surgery consultation at the San Juan Hospital in Alicante (Spain). Enviar comentarios

You may qualify if:

  • Having undergone a mastectomy and subsequent breast reconstruction as a result of breast cancer.
  • Be able to read and understand the Spanish language.
  • Have access to the internet

You may not qualify if:

  • women who have previously had a nipple tattoo;
  • women who refuse to participate in the study;
  • pregnant or breastfeeding women.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (7)

  • Hopwood P, Fletcher I, Lee A, Al Ghazal S. A body image scale for use with cancer patients. Eur J Cancer. 2001 Jan;37(2):189-97. doi: 10.1016/s0959-8049(00)00353-1.

    PMID: 11166145BACKGROUND
  • Gomez-Campelo P, Bragado-Alvarez C, Hernandez-Lloreda MJ, Sanchez-Bernardos ML. The Spanish version of the Body Image Scale (S-BIS): psychometric properties in a sample of breast and gynaecological cancer patients. Support Care Cancer. 2015 Feb;23(2):473-81. doi: 10.1007/s00520-014-2383-0. Epub 2014 Aug 19.

    PMID: 25135839BACKGROUND
  • Banos RM, Guillen V. Psychometric characteristics in normal and social phobic samples for a Spanish version of the Rosenberg Self-Esteem Scale. Psychol Rep. 2000 Aug;87(1):269-74. doi: 10.2466/pr0.2000.87.1.269.

    PMID: 11026424BACKGROUND
  • Valenzuela-Peters R, Contreras-Garcia Y, Manriquez-Vidal C. Influence of the type of work shift in Female Sexual Function Index of healthcare sector female workers. Eur J Obstet Gynecol Reprod Biol. 2017 Mar;210:39-44. doi: 10.1016/j.ejogrb.2016.12.001. Epub 2016 Dec 6.

    PMID: 27940265BACKGROUND
  • Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino R Jr. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208. doi: 10.1080/009262300278597.

    PMID: 10782451BACKGROUND
  • Sanchez-Sanchez B, Navarro-Brazalez B, Arranz-Martin B, Sanchez-Mendez O, de la Rosa-Diaz I, Torres-Lacomba M. The Female Sexual Function Index: Transculturally Adaptation and Psychometric Validation in Spanish Women. Int J Environ Res Public Health. 2020 Feb 5;17(3):994. doi: 10.3390/ijerph17030994.

    PMID: 32033334BACKGROUND
  • Morokoff PJ, LoPiccolo J. A comparative evaluation of minimal therapist contact and 15-session treatment for female orgasmic dysfunction. J Consult Clin Psychol. 1986 Jun;54(3):294-300. doi: 10.1037//0022-006x.54.3.294. No abstract available.

    PMID: 3722555BACKGROUND

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Marta Lluesma-Vidal, Ph.D

    CEU-Cardenal Herrera University, CEU universities

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant research scientist

Study Record Dates

First Submitted

March 8, 2024

First Posted

April 11, 2024

Study Start

June 1, 2024

Primary Completion

October 30, 2024

Study Completion

December 31, 2025

Last Updated

April 11, 2024

Record last verified: 2024-04

Data Sharing

IPD Sharing
Will not share